Neurotrophic keratopathy is a rare degenerative disease of the cornea that results from damage to the nerves that keep the cornea healthy. Without proper nerve function, the eye loses its natural ability to heal and protect itself, leading to serious complications that can threaten vision. Early diagnosis is essential to prevent the condition from progressing to corneal ulceration or even perforation.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing persistent eye problems, particularly if they have a history of conditions that can damage corneal nerves, should consider getting tested for neurotrophic keratopathy. The challenge with this disease is that many patients do not experience the typical warning signs of eye problems, such as pain or discomfort, because the very nerves that would send these signals are damaged.^[1]

People who have had herpes simplex or herpes zoster infections affecting the eye are especially at risk and should be monitored carefully. These viral infections are among the most common causes of neurotrophic keratopathy, as they can severely damage the corneal nerves.^[2] Similarly, individuals with diabetes mellitus should be aware that their condition may affect corneal sensation over time, making regular eye examinations important even when symptoms are not obvious.^[1]

Those who have undergone certain eye surgeries should also seek diagnostic testing if they notice any changes in their vision or eye comfort. Procedures such as LASIK (a type of laser eye surgery), corneal transplantation, or cataract surgery can sometimes damage corneal nerves during the surgical process.^[6] People who have had neurosurgery, particularly procedures involving the trigeminal nerve—the main nerve responsible for corneal sensation—are at high risk and should be screened for signs of corneal nerve damage.^[3]

Patients with chronic eye conditions, such as long-term contact lens wear, chronic dry eye syndrome, or those using topical eye medications over extended periods, should also consider diagnostic testing. Many commonly used eye drops contain preservatives that can gradually damage corneal nerves, and this damage can accumulate without causing obvious symptoms until the disease has progressed.^[3]

Diagnostic Methods

Diagnosing neurotrophic keratopathy requires a combination of careful medical history review, clinical examination of the eye, and specific tests to measure corneal sensitivity and nerve function. The diagnosis is primarily clinical, meaning doctors rely on what they observe during examination and what the patient reports about their medical background.^[7]

Medical History and Clinical Examination

The first step in diagnosing neurotrophic keratopathy involves a detailed discussion about the patient’s medical history. Doctors will ask about any previous eye infections, especially herpes virus infections, any history of diabetes or other systemic diseases, and whether the patient has had any eye surgeries or procedures that might have affected the cornea.^[3] This conversation helps identify potential causes of corneal nerve damage.

A comprehensive eye examination follows, which typically includes examination with a slit lamp, a specialized microscope that allows the doctor to view the structures of the eye in detail. During this examination, doctors look for characteristic signs of neurotrophic keratopathy, such as abnormalities in the corneal surface, persistent areas where the outer layer of the cornea has broken down, or signs of corneal swelling.^[1]

The examination of cranial nerve function is also essential, as damage to the trigeminal nerve or its branches can indicate the underlying cause of the corneal problems. Doctors may check facial sensation and other functions controlled by nearby nerves to get a complete picture of nerve health.^[4]

Corneal Sensitivity Testing

Testing corneal sensitivity is the hallmark of neurotrophic keratopathy diagnosis, as reduced or absent sensation is the defining feature of this disease. The simplest method involves gently touching the cornea with a wisp of cotton from a cotton-tipped applicator. The doctor observes whether the patient blinks reflexively or reports feeling the touch. In patients with neurotrophic keratopathy, this blink reflex is diminished or completely absent.^[3]

A more precise method uses an instrument called a Cochet-Bonnet aesthesiometer. This device has a thin nylon filament of adjustable length that is gently applied to different areas of the cornea. As the length of the filament changes, so does its stiffness. Patients with normal corneal sensation can feel the filament even when it is long and flexible, while those with reduced sensation can only detect it when it is shorter and more rigid. This test provides a quantitative measure of how severe the sensory loss is.^[3]

Corneal Staining and Surface Evaluation

To visualize damage to the corneal surface, doctors use vital dyes such as fluorescein, rose Bengal, or lissamine green. These special colored substances are applied to the eye and highlight areas where the corneal epithelium—the outermost protective layer—has broken down or is damaged. Under a blue light (cobalt blue filter), fluorescein makes these defects glow, making them easy to see and map.^[3]

The pattern and extent of staining help doctors classify the severity of the disease. In early stages, they may see only small, scattered spots of damage (punctate keratopathy). In more advanced cases, large areas of persistent epithelial defect or even deep corneal ulcers may be visible.^[2]

Disease Staging

Once neurotrophic keratopathy is diagnosed, doctors classify it into stages using the Mackie classification system, which helps guide treatment decisions. Stage 1 disease shows only superficial changes to the corneal epithelium, such as punctate keratopathy, some cloudiness, and possible early blood vessel growth into the normally clear cornea. Stage 2 is characterized by a persistent epithelial defect—an area where the protective outer layer of the cornea fails to heal—and may include swelling of the deeper layers of the cornea. Stage 3 represents severe disease, with corneal ulceration that extends into the deeper stromal layers, potentially progressing to corneal thinning (melting) or perforation.^[3]

Advanced Imaging Techniques

In some cases, particularly when the diagnosis is uncertain or when detailed information about corneal nerve health is needed, doctors may use in vivo confocal microscopy. This sophisticated imaging technique allows direct visualization and counting of corneal nerve fibers without harming the eye. Reduced nerve density or abnormal nerve appearance on these images confirms the diagnosis and provides objective evidence of nerve damage.^[3]

This technology is especially useful because it can detect nerve damage before clinical symptoms become obvious, potentially allowing earlier intervention. It also helps distinguish neurotrophic keratopathy from other conditions that may look similar on routine examination.^[7]

Additional Diagnostic Tests

Doctors often perform tests to evaluate the health of the tear film and overall ocular surface, as these factors can influence the course of neurotrophic keratopathy. The Schirmer test measures tear production by placing a small strip of paper inside the lower eyelid and measuring how much moisture accumulates over a set period. The tear film break-up time test assesses how stable the tear film is by measuring how long it takes for dry spots to appear on the cornea after a blink.^[3]

If infection is suspected as a complicating factor, doctors may take samples from the cornea for microbiological examination. This is particularly important because eyes with neurotrophic keratopathy are more vulnerable to bacterial infections, which can worsen the condition significantly.^[3]

Differential Diagnosis

Part of the diagnostic process involves ruling out other conditions that may present with similar symptoms. These include various forms of dry eye disease, exposure keratitis (corneal damage from incomplete eyelid closure), deficiency of corneal stem cells, toxicity from topical medications, contact lens-related problems, infectious corneal diseases, and certain corneal dystrophies. The key distinguishing feature of neurotrophic keratopathy is the presence of reduced or absent corneal sensation, which is why corneal sensitivity testing is so crucial.^[3]

Diagnostics for Clinical Trial Qualification

When patients with neurotrophic keratopathy are considered for enrollment in clinical trials testing new treatments, they typically undergo additional standardized diagnostic procedures beyond those used in routine clinical practice. These tests help ensure that trial participants meet specific criteria and allow researchers to accurately measure whether experimental treatments are working.^[6]

Clinical trials generally require objective documentation of reduced corneal sensitivity using standardized methods. While the simple cotton wisp test may be sufficient for clinical diagnosis, trials often mandate the use of Cochet-Bonnet aesthesiometry with specific threshold measurements. For example, a trial might require that patients have corneal sensitivity measurements below a certain threshold to qualify for participation.^[6]

Accurate staging of the disease using the Mackie classification system is typically required for trial enrollment. Researchers often use standardized photography and detailed documentation of corneal defects, including precise measurements of the size and location of any epithelial defects or ulcers. High-resolution imaging may be performed at baseline and at regular intervals throughout the study to track healing progress.^[2]

In vivo confocal microscopy is increasingly used in clinical trials as an objective way to measure corneal nerve density and morphology. This provides quantifiable data about nerve health that can be tracked over time to determine if a treatment is helping to restore corneal innervation. Some trials may also use specialized nerve staining techniques or other advanced imaging modalities to assess nerve regeneration.^[7]

Comprehensive ocular surface assessment is standard in clinical trials for neurotrophic keratopathy. This includes detailed tear film evaluation with Schirmer tests and tear break-up time measurements, as well as standardized grading of corneal and conjunctival staining patterns using validated scoring systems. These assessments help researchers understand the overall health of the ocular surface and how it changes with treatment.^[6]

Visual acuity testing is performed using standardized protocols to document baseline vision and track any improvements or deterioration during the trial. Because neurotrophic keratopathy can significantly impact vision, especially when the center of the cornea is affected, measuring visual outcomes is an important part of assessing treatment effectiveness.^[2]

Clinical trials may also require microbiological testing to rule out active infection before enrollment, as infections can complicate interpretation of treatment effects. Regular monitoring for infection throughout the trial period is also common, given that neurotrophic keratopathy increases vulnerability to bacterial superinfection.^[1]

Quality of life assessments and patient-reported outcome measures are increasingly incorporated into clinical trials. These questionnaires help capture how the disease and its treatment affect daily life, comfort, and visual function from the patient’s perspective. This information complements the objective clinical measurements and provides a more complete picture of treatment impact.^[6]